Last reviewed · How we verify

Sodium Citrate 4% Inj Syringe 3Ml

Johns Hopkins University · FDA-approved active Small molecule Quality 3/100

Sodium Citrate 4% Inj Syringe 3Ml is a Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved. Also known as: ANDA BA125608 / Sodium Citrate 4% w/v Anticoagulant Solution USP.

At a glance

Generic nameSodium Citrate 4% Inj Syringe 3Ml
Also known asANDA BA125608 / Sodium Citrate 4% w/v Anticoagulant Solution USP
SponsorJohns Hopkins University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sodium Citrate 4% Inj Syringe 3Ml

What is Sodium Citrate 4% Inj Syringe 3Ml?

Sodium Citrate 4% Inj Syringe 3Ml is a Small molecule drug developed by Johns Hopkins University.

Who makes Sodium Citrate 4% Inj Syringe 3Ml?

Sodium Citrate 4% Inj Syringe 3Ml is developed and marketed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).

Is Sodium Citrate 4% Inj Syringe 3Ml also known as anything else?

Sodium Citrate 4% Inj Syringe 3Ml is also known as ANDA BA125608 / Sodium Citrate 4% w/v Anticoagulant Solution USP.

What development phase is Sodium Citrate 4% Inj Syringe 3Ml in?

Sodium Citrate 4% Inj Syringe 3Ml is FDA-approved (marketed).

Related